ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

SURVEY: Cognitive Impairment II

Top 3 Nutrients to Detox the Liver and Soothe Digestion

Natural Bladder Control, Go Less and Live More

Vital Molecule Increases Cellular Energy and Improves Cognitive Function

Top Vitamin and Mineral Deficiencies — Are You at Risk?

How Pomegranate May Protect Against Cancer

Omega Fix for Obesity: How the Right Fats Fight Fat

Trimming the spare tire: Canola oil may cut belly fat

The Onion: Cancer Fighter and Food Preserver

Fighting Heartburn and Gerd Naturally – And Safely!

 
Print Page
Email Article

The Memory Impairment Study

  [ Not Yet Rated ]   [ Discuss This Article ]
By 1999 Progress Report by the NIA/NIH • www.ProHealth.com • December 13, 1999


A highlight of NIA's effort to develop effective therapies for AD is the Memory Impairment Study, launched by the Institute in March, 1999. This study is based on the premise that accurate and early evaluation and treatment of individuals with MCI might prevent further cognitive decline, including development of AD. The publication of the earlier research that confirmed that MCI is a distinct clinical entity and, for the first time, characterized its symptoms (see p. 31 for a fuller description of this study), provided a critical foundation for the Memory Impairment Study (Petersen et al., 1999).

The Memory Impairment Study is the first AD prevention clinical trial to be carried out by NIH and is being conducted by the Alzheimer's Disease Cooperative Study (ADCS), an established nationwide network of research centers supported by the NIA and coordinated by the University of California at San Diego. The ADCS sites will be joined by other clinics and centers around the U.S. and Canada. About 65 sites are participating in the study. The Memory Impairment Study is supported by grant funding from the NIA as well as by contributions from Pfizer, Inc., and Eisai, Inc. Additional support comes from Roche Vitamins, Inc.

Before this study, most treatments tested for slowing memory decline were evaluated in patients with well-defined AD. This trial will test the ability of two agents --vitamin E and donepezil--to intervene earlier, before signs of memory impairment have developed into clinically diagnosed AD. Investigators want to see whether these agents can delay or prevent the onset of AD. The study will be carried out over a 3-year period in 720 people with MCI. The major requirements for participation in the study include recent memory complaints, abnormal memory function on standardized tests, good general health, and no clinical diagnosis of AD. Participants will be randomly assigned to one of three groups--the first group will receive vitamin E, a placebo for donepezil, and a multivitamin; the second group will receive a placebo for vitamin E, donepezil, and a multivitamin; and the third group will receive placebos for vitamin E and donepezil and a multivitamin.

A major challenge for this trial is screening and recruiting individuals who are diagnosed with MCI. Recruitment for AD clinical trials traditionally involves working with Alzheimer's Disease Centers or other memory disorders clinics to recruit existing patients with clinically diagnosed AD. Because MCI has only recently been defined as a distinct clinical entity, individuals with MCI are not so readily available. To meet this challenge, NIA has developed new recruitment procedures to make people aware of the trial, allow them to sign up, and provide a means for them to come to the study site for a full diagnostic evaluation, treatment, and follow-up. The recruitment procedures developed will be critically important not only for the success of this clinical trial but also for other trials that seek to develop treatments for preventing or delaying the onset of Alzheimer's.

Source:
National Institutes of Health
National Institute on Aging
1999 PROGRESS REPORT ON ALZHEIMER'S DISEASE



Post a Comment

Featured Products From the ProHealth Store
FibroSleep™ Mitochondria Ignite™ with NT Factor® Vitamin D3 Extreme™


Article Comments



Be the first to comment on this article!

Post a Comment


 
Natural Pain Relief Supplements

Featured Products

Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium

Natural Remedies

Health Benefits Are Brewing in Green Tea Health Benefits Are Brewing in Green Tea
Itching to Find Dry Skin Relief? Itching to Find Dry Skin Relief?
How I Found My Long-Lost Energy How I Found My Long-Lost Energy
Prepare Yourself for Cold & Flu Season Prepare Yourself for Cold & Flu Season
Stop Bacteria With Nature's Antibiotics Stop Bacteria With Nature's Antibiotics

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map